EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. The company’s lead programs include a Nicotinic Acetylcholine Receptor Agonist Program for Alzheimer’s disease, a Histone Deacetylase (HDAC) Inhibitor Program for Huntington’s disease, a Gamma Secretase Modulator (GSM) Program for disease modifying treatment of Alzheimer’s disease and a Phospho-Diesterase 10 (PDE10) Program for Schizophrenia.
|